Difference between revisions of "Asciminib (Scemblix)"
Jump to navigation
Jump to search
m |
|||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allosteric-bcr-abl-tyrosine-kinase-inhibitor-abl001 NCI Drug Dictionary]: An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, asciminib binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allosteric-bcr-abl-tyrosine-kinase-inhibitor-abl001 NCI Drug Dictionary]: An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, asciminib binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Chronic myelogenous leukemia]] | |
| − | # | + | |
| + | ==History of changes in FDA indication== | ||
| + | *10/29/2021: Granted accelerated approval for patients with [[Biomarkers#BCR-ABL1|Philadelphia chromosome-positive]] [[Chronic myelogenous leukemia|chronic myeloid leukemia]] (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). ''(Based on ASCEMBL)'' | ||
| + | *10/29/2021: Approved for adult patients with [[Biomarkers#BCR-ABL1|Ph+]] [[Chronic myelogenous leukemia|CML]] in CP with the [[Biomarkers#T315I|T315I]] mutation. ''(Based on CABL001X2101)'' | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' ABL001 | *'''Code name:''' ABL001 | ||
| + | *'''Brand name:''' Scemblix | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:Bcr-Abl inhibitors]] | [[Category:Bcr-Abl inhibitors]] | ||
| − | + | [[Category:Chronic myelogenous leukemia medications]] | |
| − | [[Category: | + | [[Category:FDA approved in 2021]] |
Revision as of 21:42, 29 October 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, asciminib binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies.
Diseases for which it is used
History of changes in FDA indication
- 10/29/2021: Granted accelerated approval for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Based on ASCEMBL)
- 10/29/2021: Approved for adult patients with Ph+ CML in CP with the T315I mutation. (Based on CABL001X2101)
Also known as
- Code name: ABL001
- Brand name: Scemblix